Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex versus neostigmine for reversal of deep rocuronium-induced neuromuscular blockade in children
2011-000401-50Phase 3Active
- Sponsor
- Fundación para la Formación e Investigación Sanitaria
- Start
- Sep 2011
- Modality
- Classical Binding Small Molecules → Small Molecules, Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3 trial of Sugammadex, neostigmine, rocuronium and atropine in neuromuscular block (NMB) (2 arms), sponsored by Fundación para la Formación e Investigación Sanitaria. Primary endpoint: Time to recovery of T4/T1 ratio greater than 0.9. Started Sep 2011; status: active.
02
Drugs
Sugammadexneostigminerocuroniumatropine
03
Conditions
neuromuscular block (NMB)
Beyond the preview
Go deeper on 2011-000401-50.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000401-50.